Brief Title
Ultrasensitive Positron Emission Tomography in NPC Patients
Official Title
Subsecond Total-body Imaging Using Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients
Brief Summary
Ultrasensitive PET in newly diagnosed nasopharyngeal carcinoma may benifit the patients.
Detailed Description
A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. The objective of this study is to determine its specific effect in newly diagnosed nasopharyngeal carcinoma
Study Type
Observational [Patient Registry]
Primary Outcome
The results of ultrasensitive positron emission tomography
Condition
Nasopharyngeal Carcinoma
Intervention
ultrasensitive positron emission tomography
Study Arms / Comparison Groups
Ultrasensitive PET CT
Description: Newly diagnosed NPC patients will undergo ultrasensitive PET CT before treatment
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
20
Start Date
June 20, 2020
Completion Date
June 20, 2021
Primary Completion Date
February 20, 2021
Eligibility Criteria
Inclusion Criteria: - Patients must be informed of the investigational nature of this study and given written informed consent. - Aged between 18-65, male/female. - Histologically confirmed non-keratinizing nasopharyngeal carcinoma (including differentiated type and undifferentiated type, WHO II and III).. - Fertile women should practice contraception during the study period. - HGB ≥90g/L ,WBC ≥4*109/L , PLT ≥100*109/L, - With normal liver function test (ALT and AST ≤2.5*ULN, TBil ≤2.0*ULN) - With normal renal function test (serum creatinine ≤1.5*ULN) Exclusion Criteria: - Women in pregnancy or lactation - Prior malignancy except adequately treated basal cell, squamous cell skin cancer, or cervical cancer in situ. - Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), and emotional disturbance. - Already involved in other clinical trial. - Mental disorder, civil disability, limited capacity for civil conduct.
Gender
All
Ages
18 Years - 65 Years
Contacts
Haiqiang Mai, Dr, 86-20-8734-3643, [email protected]
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT04394065
Organization ID
2020-5-13 high-sensitivity PET
Responsible Party
Principal Investigator
Study Sponsor
Sun Yat-sen University
Study Sponsor
Haiqiang Mai, Dr, Principal Investigator, Sun Yat-sen University
Verification Date
January 2021